


PHARMACEUTICAL 2017

Insys Therapeutics Inc. Rank 13 of 313







RealRate

Insys Therapeutics Inc. Rank 13 of 313

The relative strengths and weaknesses of Insys Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Insys Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 491% points. The greatest weakness of Insys Therapeutics Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 302% points.

The company's Economic Capital Ratio, given in the ranking table, is 192%, being 609% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	230,972
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	78,614
Liabilities, Non-Current	0
Other Assets	81,992
Other Compr. Net Income	-150
Other Expenses	210,390
Other Liabilities	7,933
Other Net Income	0
Property and Equipment	43,172
Research and Development	0
Revenues	242,275
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	356,136
Liabilities	86,547
Expenses	210,390
Stockholders Equity	269,589
Net Income	31,885
Comprehensive Net Income	31,810
Economic Capital Ratio	192%

